The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
An exhaustive analysis of the UK market including every firm in the top 200 ranked, analysed and benchmarked, UK chambers ranked by turnover, revenue per barrister and which international firms are most active in the UK.
Ashurst Morris Crisp has acted for biotech company Ark Therapeutics on a £14.4m secondary equity financing. The share issue valued Ark at £62m. Funds were subscribed by financial institutions that included Nomura International, Merlin, BankInvest, Gartmore and Northern Ventures. Ashursts head of life sciences and IT Mark Lubbock led the team for Ashursts, and Ashursts lawyer David Arnold acted for Gartmore. KLegal partner Patrick Martin advised Merlin, Simmons & Simmons partner Mark Curtis acted for Nomura and BankInvest and Dickinson Dees partner Chris Harker acted for Northern Ventures. Ashursts advised Ark last year when it raised £15m equity financing, the largest private fundraising in the sector. Nick Plummer, corporate lawyer at Ashursts, said: "I think £14.4m is impressive, especially considering that they raised so much last year."